# Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease

> **NCT07280299** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Gain Therapeutics, Inc.** · enrollment: 111 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Low Dose GT-02287
- **DRUG:** High Dose GT-02287
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07280299
- **Lead sponsor:** Gain Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07280299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07280299, "Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07280299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*